External Validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score

Zhao, Kevin; Hernandez, David J.; Han, Misop; Humphreys, Elizabeth B.; Mangold, Leslie A.; Partin, Alan W.

doi:10.1016/j.urology.2007.11.165

Cited by 51 publications

(42 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study at a single center shows that the CAPRA score predicts BCR after RP only to some degree in Japanese patients, although the outcome was inversely better for the intermediate CAPRA score 4. The c-index of 0.673 in the present study is comparable with the c-index of 0.66 in the original CaPSURE cohort [5], but is lower than the c-indices reported in the other validation cohorts, which range from 0.68 to 0.81 [6,7,8,9]. When applying the modified 3-group CAPRA score, the c-index increased, and reasonable calibration was shown.…”

Section: Discussionsupporting

confidence: 69%

“…At present, the CAPRA score has been validated in several other cohorts, including a multi-institutional cohort (the Shared Equal Access Regional Cancer Hospital database) [6], a multi-institutional German series [7], a Johns Hopkins series involving 6,737 patients [8] and a single-surgeon series [9], and was shown to accurately predict BCR-free rate after RP. The CAPRA score was also reported to predict metastases and cancer-specific mortality with good accuracy among the CaPSURE cohort treated with RP, radiation therapy, hormonal therapy or watchful waiting [13].…”

Section: Discussionmentioning

confidence: 99%

“…High-risk patients might have tended to receive adjuvant therapy preoperatively. Because the aim of the present study was to determine the relationship between the CAPRA score and BCR after RP without the influence of adjuvant therapy, the exclusion of patients undergoing adjuvant therapy was conducted similarly to that in the other external validation studies [8,9]. Thus, the assessment of high-risk patients may be insufficient in the present study.…”

Section: Discussionmentioning

confidence: 99%

“…The CAPRA score provides more detailed and accurate risk stratification data than does the D’Amico risk classification but offers easier calculation and application than that of the Stephenson nomogram. Currently, the CAPRA score has been well validated in several other cohorts and has been shown to accurately predict BCR after RP [6,7,8,9]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients

Yoshida¹,

Nakayama²,

Takeda³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objectives: The aim of the present study was external validation to determine whether the Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical relapse (BCR) after radical prostatectomy (RP) in Japanese patients. Methods: From 1995 to 2008, 503 Japanese patients undergoing RP for clinically localized prostate cancer were included in the validation cohort. The BCR-free rate was estimated using the Kaplan-Meier method. Performance of the CAPRA score was assessed using Cox proportional hazards regression models, concordance index (c-index) and calibration plots. Results: Unlike the results in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) cohort, the BCR-free rate and the hazard ratio for CAPRA score 4 were inversely better than those for CAPRA scores 2 and 3 in Japanese patients. The c-index of the CAPRA score was 0.673. The calibration plot demonstrated that the CAPRA score was generally well calibrated. Conclusions: In Japanese patients, the CAPRA score can predict BCR after RP only to some degree. Although our c-index is comparable with the c-index of 0.66 in the original CaPSURE cohort, it is lower than the c-indices reported in other validation cohorts, which range from 0.68 to 0.81. The CAPRA score may not predict BCR after RP in Japanese patients as accurately as it did in Western patients.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients

Yoshida¹,

Nakayama²,

Takeda³

et al. 2012

Urol Int

View full text Add to dashboard Cite

show abstract

“…16 Because detailed biopsy data are not included in J-CaP, a previously published modification of the CAPRA score was used, which omits the percent of positive cores variable and calculates the score on a 0 to 9 rather than 0 to 10 scale. 17 For patients missing exactly one input variable needed to calculate the score, the score was imputed using least squares regression; the distribution of imputed CAPRA scores was similar to the distribution of nonimputed scores. These instruments are all intended to stratify patients with localized disease; in this study those with "advanced" disease (clinical stage Ͼ T3aN0M0) were categorized separately as advanced.…”

Section: Applying Standard Risk Instruments To Padt Patientsmentioning

confidence: 99%

Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy

Cooperberg

Hinotsu

Namiki

et al. 2009

JCO

115

135

View full text Add to dashboard Cite

A B S T R A C T PurposeProstate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients. MethodsData were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments. ResultsJ-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43% of J-CaP versus 5% of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA-scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage-predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84. ConclusionThe novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.

show abstract

Prostate cancer risk assessment

Cooperberg

2008

Cancer

View full text Add to dashboard Cite

show abstract

External Validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score

Cited by 51 publications

References 12 publications

External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients

External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients

Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy

Prostate cancer risk assessment

Contact Info

Product

Resources

About